The World Health Organization has approved a new anti-malaria vaccine, which will offer countries a cheap and more accessible option to combat one of the leading causes of child deaths in Africa.
Developed by Oxford University, the R21/Matrix-M vaccine is the second such vaccine to be recommended by the WHO, it said in a statement Monday.
The recommendation, based on preclinical and clinical trial data, showed that the vaccine reduced symptomatic cases by 75 percent following a three-dose series in a year, in areas with high seasonal malaria transmission. The Phase III clinical trial results are under peer review, Oxford said in a statement.
At a cost of $2-4 per dose, R21 was a cost-effective intervention, the WHO said, adding that it expects the vaccine to be available by mid-2024. “As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two,” WHO Director General Tedros Adhanom Ghebreyesus said in the statement.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.